文献速递肺栓塞与肺血管病

血管生成素-2在静脉血栓溶解及慢性血栓栓塞性疾病中的作用

Role of angiopoietin-2 in venous thrombus resolution and chronic thromboembolic disease.
PubMed 文献 · Eur Respir J · 2021-12-02

本研究测量了CTEPH和急性肺栓塞患者的血浆ANGPT2水平,并分析PEA标本及小鼠模型。发现CTEPH患者ANGPT2升高且PEA后下降,小鼠中ANGPT2过表达延迟血栓溶解,提示ANGPT2促进血栓纤维化并可能参与肺栓塞向CTEPH转化。

要点

  • CTEPH患者循环ANGPT2水平升高,PEA术后下降。
  • 小鼠中ANGPT2过表达延迟静脉血栓溶解。
  • ANGPT2可能促进血栓纤维化及肺栓塞向CTEPH转化。

核心结论

  • ANGPT2延迟静脉血栓溶解,其过表达促进血栓纤维化并可能支持肺栓塞向CTEPH转化。

研究设计与样本

  • 测量CTEPH患者(n=68)和急性肺栓塞患者(n=84)血浆ANGPT2浓度。
  • 对CTEPH行PEA术切除的组织进行(免疫)组织学分析。
  • 使用下腔静脉结扎小鼠模型,研究经渗透泵给予重组ANGPT2的野生型小鼠及内皮细胞过表达ANGPT2的转基因小鼠静脉血栓溶解动力学。

主要发现

  • CTEPH患者循环ANGPT2水平高于特发性肺动脉高压患者和健康对照,且PEA后下降。
  • 肺栓塞患者血浆ANGPT2升高,随访期间诊断CTEPH。
  • PEA标本组织学分析证实ANGPT2表达增加,早期机化肺血栓、肌成纤维细胞和纤维化区域磷酸化TIE2水平低。
  • 微阵列和高分辨率显微镜分析将ANGPT2过表达定位至内皮细胞,缺氧和TGF-β1被确定为潜在刺激因素。
  • 小鼠功能获得实验显示外源性ANGPT2给药和转基因内皮ANGPT2过表达导致静脉血栓溶解延迟,血栓特征为TIE2磷酸化降低和微血管减少。

临床怎么用

  • ANGPT2可能作为肺栓塞后血栓溶解不良及CTEPH发生的生物标志物。
  • 靶向ANGPT2/TIE2通路或有助于促进血栓溶解和预防CTEPH。

局限性

  • 原文未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Defective angiogenesis, incomplete thrombus revascularisation and fibrosis are considered critical pathomechanisms of chronic thromboembolic pulmonary hypertension (CTEPH) after pulmonary embolism. Angiopoietin-2 (ANGPT2) has been shown to regulate angiogenesis, but its importance for thrombus resolution and remodelling is unknown. METHODS: ANGPT2 plasma concentrations were measured in patients with CTEPH (n=68) and acute pulmonary embolism (n=84). Tissue removed during pulmonary endarterectomy (PEA) for CTEPH was analysed (immuno)histologically. A mouse model of inferior vena cava ligation was used to study the kinetics of venous thrombus resolution in wild-type mice receiving recombinant ANGPT2 via osmotic pumps, and in transgenic mice overexpressing ANGPT2 in endothelial cells. RESULTS: Circulating ANGPT2 levels were higher in CTEPH patients compared to patients with idiopathic pulmonary arterial hypertension and healthy controls, and decreased after PEA. Plasma ANGPT2 levels were elevated in patients with pulmonary embolism and diagnosis of CTEPH during follow-up. Histological analysis of PEA specimens confirmed increased ANGPT2 expression, and low levels of phosphorylated TIE2 were observed in regions with early-organised pulmonary thrombi, myofibroblasts and fibrosis. Microarray and high-resolution microscopy analysis could localise ANGPT2 overexpression to endothelial cells, and hypoxia and transforming growth factor-β1 were identified as potential stimuli. Gain-of-function experiments in mice demonstrated that exogenous ANGPT2 administration and transgenic endothelial ANGPT2 overexpression resulted in delayed venous thrombus resolution, and thrombi were characterised by lower TIE2 phosphorylation and fewer microvessels. CONCLUSION: Our findings suggest that ANGPT2 delays venous thrombus resolution and that overexpression of ANGPT2 contributes to thrombofibrosis and may thus support the transition from pulmonary embolism to CTEPH.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Hobohm L, Kölmel S, Niemann C, et al. Role of angiopoietin-2 in venous thrombus resolution and chronic thromboembolic disease. Eur Respir J. 2021. PMID: 33986029. doi:10.1183/13993003.04196-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。